Celladon to report results of its gene therapy for heart failure: CEO

April 8, 2015 8:40 PM

3 0

(Reuters) - Celladon Corp expects to report this month results from a key trial of Mydicar, its experimental gene therapy for advanced heart failure, a condition in which the heart muscle cannot pump enough blood to meet the body's needs.

The upcoming results are seen as a big test for the more than 20-year-old field, which has re-emerged after a series of disappointments and safety concerns. On Monday, Bristol-Myers Squibb Co acquired a nearly 5 percent stake in uniQure NV, sending shares of the Dutch gene therapy producer up 55 per...

Read more

To category page